Morgan Stanley raised the firm’s price target on BioNTech (BNTX) to $140 from $139 and keeps an Overweight rating on the shares. The firm ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $139.00.

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where BioNTech SE (NASDAQ:BNTX) stands against other ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

Nevertheless, BNTX’s robust balance sheet makes it cheap relative to its long-term potential. It also de-risks the company until it refocuses on oncology. In my view, BioNTech's long-term value ...

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading today, for the June 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

BioNTech SE (NASDAQ:BNTX) just released its full-year report and things are looking bullish. Results overall were credible, with revenues arriving 3.9% better than analyst forecasts at €2.8b.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued ...